ConsumerAffairs7h
FDA approves Zepbound as a treatment for obstructive sleep apnea
Zepbound is Eli Lilly’s weight loss drug. Now, it is also a drug to treat obstructive sleep apnea (OSA).The U.S. Food and ...
MedPage Today3d
FDA Says Compounded Tirzepatide Must Exit the Market
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
FiercePharma3d
FDA reaffirms decision to erase Eli Lilly's tirzepatide from shortage list, halting future flow of knockoffs
The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...
STAT2d
Is a contrarian leader good for the FDA?
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
FDA keeps Mounjaro off shortage list after reevaluation
The Food and Drug Administration (FDA) has reaffirmed that Mounjaro and Zepbound are no longer in shortage following a ...
Investing3d
Hims & Hers shares tumble as FDA resolves obesity drug shortage
The FDA's latest decision could reshape the market dynamics for obesity drugs, as compounded versions were allowed under U.S. regulations during the shortage. Hims & Hers Health's stock movement today ...
STAT5d
A key decision on compounding is expected this week
To refresh: In early October, the FDA pulled Eli Lilly’s tirzepatide off its drug shortage list after nearly two years.
BioSpace4d
FDA Issues Warning Letters Against GLP-1 Compounders
The letters come amid the Outsourcing Facilities Association’s ongoing lawsuit against the FDA over the regulator’s decision ...